Anti-Bevacizumab (Avastin®)
- SKU:
- TM09012
- Bulk Pricing:
-
- Buy 5 - 20 and get 5% off
- Buy 21 - 30 and get 10% off
- Buy 31 - 50 and get 15% off
- Buy 51 or more – call for best pricing
The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.
ImmunoGuide® Enzyme immunoassay (ELISA) test kit for the determination of free antibodies to Bevacizumab in serum and plasma.<br><br>
The drug Bevacizumab (trade name Avastin®) is a recombinant human IgG1:monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms and it has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration. As with all therapeutic proteins, there is a potential for immunogenicity. According to the manufacturer’s product insert; the incidence of antibody development in patients receiving Bevacizumab has not been adequately determined because the assay sensitivity was inadequate to reliably detect lower titers.<br><br>
The ImmunoGuide Antibody to Bevacizumab ELISA Kit can be used for monitoring anti-Bevacizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures. For research use only, not for use in diagnostic procedures.
ImmunoGuide® Enzyme immunoassay (ELISA) test kit for the determination of free antibodies to Bevacizumab in serum and plasma.<br><br>
The drug Bevacizumab (trade name Avastin®) is a recombinant human IgG1:monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms and it has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration. As with all therapeutic proteins, there is a potential for immunogenicity. According to the manufacturer’s product insert; the incidence of antibody development in patients receiving Bevacizumab has not been adequately determined because the assay sensitivity was inadequate to reliably detect lower titers.<br><br>
The ImmunoGuide Antibody to Bevacizumab ELISA Kit can be used for monitoring anti-Bevacizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures. For research use only, not for use in diagnostic procedures.